GlassScriptPhysician profile
Marc S Rovner
NPI 1093795668
$70,610.60
in general payments reported to CMS, 2019-2025
23 companies · $18K in 2025
The $18K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $47.95 · 2021: $700 · 2022: $7,847 · 2023: $18K · 2024: $26K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $5,779 · Consulting Fee: $5,348 · Food and Beverage: $4,288 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,245.00 |
| Travel and Lodging | $5,779.18 |
| Consulting Fee | $5,347.50 |
| Food and Beverage | $4,288.21 |
| Education | $121.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $61,449.87 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Amgen INC. | $5,981.02 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $762.10 | 2019-2025 | Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $509.99 | 2021-2025 | Dupixent |
| Astrazeneca Uk Limited | $465.00 | 2025 | Tezspire |
| Genzyme Corporation | $235.45 | 2024-2025 | |
| Pulmonx Corporation | $144.74 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $126.05 | 2023-2025 | Glassia, Cuvitru, Takhzyro |
| Depuy Synthes Sales INC. | $123.97 | 2021 | |
| Alexion Pharmaceuticals, INC. | $109.65 | 2022 | |
| Mylan Specialty L.P. | $98.53 | 2024 | Yupelri |
| Insmed, INC. | $94.60 | 2024-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Viatris Specialty LLC | $75.33 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $74.25 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $49.80 | 2024 | Zemaira |
| Genentech USA, INC. | $47.95 | 2020 | |
| Vapotherm INC | $32.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.47 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.03 | 2025 | Xifaxan |
| Covidien LP | $13.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Rovner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.